AGC Biologics Invests in New Viral Vector Suspension Capabilities at U.S. Cell & Gene Hub
SEATTLE, May 18 (Bernama-GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it is adding viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Col., USA. These new capabilities, which begin coming online in…

